Catherine has over 10 years of experience in the biotech industry, primarily in drug discovery with a focus on immuno-oncology and translational science. Catherine has an MSc by Research in cancer cell biology from the University of Bristol. She has expertise in establishing methods to assess drug mechanism, target engagement and PD biomarkers in both pre-clinical and clinical studies.
As lead scientist, Catherine develops complex primary immune cell assays, utilising the innovative analysis capabilities available at Medicines Discovery Catapult to support immunology drug discovery projects.
